• Busca personas
• Intranet

Farmacia integrada y traslacional Pau Riera

Publicaciones 2026 (10)

• Guiu JM^*, Imaz A, Espada-Trespalacios X, García Lorenzo A, García V, Guerri-Fernandez R, Hernandez J, Llobet R, Mansilla R, Masip M, Massana N, Navarro-Vilasaro M, Negredo E, Ricart A, Rudi Sola N, Colom J. actHIVa Cataluña: Consensus to improve comprehensive care and long-term quality of life for vulnerable people living with HIV in Catalonia. Enferm Infecc Microbiol Clin 2026; 44(7): 503218.
• Echeverria P^*, Puig J, Martínez A, Arrieta I, Arnau I, Bailón L, Estany C, Lemos B, Bonjoch A, Guerri-Fernandez R, Negredo E. Gender-Specific Determinants of Frailty in Aging People with HIV: Evidence for a Multidimensional Vulnerability Phenotype in Women. Viruses 2026; 18(7): 742.
  Cites:0
  Cites:0
• Pérez Molina JA, Suárez Robles M, Sánchez López MB, Tejerina F, Peñaranda M, Vera M, Goenaga Sánchez MÁ, Bernal Morell E, Peña I, Moreno S, Jarrín I, CoRIS Cohort (...,Guerri-Fernandez R, Navarro C, Du J, Marcos A, Arrieta I, Cañas-Ruano E, Canepa-Landajo C, García-Giralt N,...). Persistence of late HIV diagnosis and poorer response to antiretrovirals: a comparison between migrants and native-born people with HIV in Spain. Clin Microbiol Infec 2026; 32(8): 1311-1321.
  Cites:0
  Cites:0
• Álvarez-Pedrerol M, Polo-Alonso S, Ramos R, Martí-Lluch R, Pinsach-Abuin ML, Dégano IR, Elosua R, Subirana I, Hernáez A, Selga E, Puigdecanet E, Pruneda J, Solà C, Puigmulé M, Perez A, Nogués X, Masclans JR, Guerri-Fernandez R, Cubero H, Tizón-Marcos H, Vaquerizo B, Brugada R, Camps-Vilaró A^*, Marrugat J. Sex Differences in Long COVID Prevalence Over One year After the Acute Phase, and Related Risk Factors. The GINA-COVID Cohort Study. Int J Womens Health 2026; 18: 538491 (Acceptat).
  Cites:0
  Cites:0
• Gómez-Zorrilla S, Sendra E, Du J, Espona M, Fierro-Villegas A, Siverio-Pares A, Rodriguez-Alarcon A, Espinosa S, Lopez Montesinos I, Plata C, Arrieta Aldea, I, Soldado-Folgado J, García-Giralt N, Vicente R^*, Guerri-Fernandez R^*. Zinc adjuvant treatment in SARS-CoV-2: A randomized clinical trial. J Trace Elem Med Bio 2026; 92: 127778.
  Cites:0
  Cites:0
• Rogg L^*, Nuñez SA, Mingrone MV, Domingo P, Rolle CP, Guerri-Fernandez R, Estrada V, Lopez M, Hanan N, Ghita GL, Jeffrey JL, Underwood M, Castillo Mancilla JR, Halliday F, Ezeadi E, Gartland M. Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clin Infect Dis 2026: (en Premsa).
  Cites:0
  Cites:0
• Martín-Quiros A, Soriano A, Tejerina-picado F, Guerri-Fernandez R, Cotarelo M, Molloy B, Fernández Vigo E, Chacón F^*. Baseline medication profile and risk of CYP3A4 mediated drug-drug interactions among COVID-19 hospitalized patients in Spain. BMC Infect Dis 2026; 26(1): 45.
  Cites:0
  Cites:0
• Garcia Vives E^*, Rodríguez-Morera J, Brase A, Rial A, Gimenez C, Mora-Luján JM, Llaberia M, Soldado-Folgado J, Cos ML, Petit I, Campodarve I, Nogués X. Clinical predictors of malignancy in lymphadenopathy: A multivariable analysis from a quick diagnosis unit. Clin Med 2026; 26(3): 100567.
  Cites:1
  Cites:1
• Hernandez Pereira M, Du J, Soldado-Folgado J, Carbonell I, Trenchs Rodriguez M, González Mena A, García-Giralt N, Guerri-Fernandez R^*. Cross-sectional comparison of cardiovascular risk scores in people with HIV. HIV Med 2026; 27(39: 361-372.
  Cites:0
  Cites:0
• Palacio JA^*, Moreno-Fornes S, Díaz Y, Bruguera A, Llibre JM, Knobel H, Chivite I, Miró JM, Domingo P, Suanzes P, Campins A, Navarro G, Macorigh L, Mera A, Casabona J, Imaz A, Reyes JM, PISCIS study group. Where did they go? Describing and reengaging people with HIV lost to follow-up in the PISCIS Cohort Study. AIDS 2026; 37: 1990-2001.
  Cites:0
  Cites:0